



Embargo : Brussels, July 27, 2007 at 7:30 AM

## Solvay's operating results of EUR 616 million for the 1<sup>st</sup> half of 2007, exceeding the excellent results for the 1<sup>st</sup> half of 2006

- **Sales** (EUR 4,808 million) stable (+1%)
- **Operating results** of EUR 616 million exceeding (+3%) the results for the 1<sup>st</sup> half of 2006 :
  - Continued growth in **Chemicals** (+10%) and **Plastics** (+13%)
  - **Results in Pharmaceuticals** down (-16%): impact of USD, effects of Pantoloc® and pressure on prices in France as expected; decrease of miscellaneous revenues in the 2<sup>nd</sup> quarter
- **Net income of the Group** (EUR 413 million) down 15%, due to a decrease of EUR 51 million of non-operating items<sup>1</sup> and higher taxes compared to the 1<sup>st</sup> half of 2006
- **Confirmation of outlook for operating results for 2007 comparable to the results for 2006 for the Group as for Pharmaceuticals**
- **Acceleration of geographic expansion in emerging markets**

**Sales** reached EUR 4,808 million in the 1<sup>st</sup> half 2007 and were stable (+1%) compared to the 1<sup>st</sup> half of 2006. In the 2<sup>nd</sup> quarter of 2007, they were up 2% and amounted to EUR 2,436 million. At constant exchange rates, they would have increased by 4% (+4% in the 2<sup>nd</sup> quarter of 2007).

**REBIT**<sup>2</sup> (EUR 616 million) was up 3% compared to the 1<sup>st</sup> half 2006 and reached EUR 291 million in the 2<sup>nd</sup> quarter (-4% compared to the 2<sup>nd</sup> quarter of 2006). After a 1<sup>st</sup> quarter comparable to that of last year, results from the Pharmaceuticals Sector were down in the 2<sup>nd</sup> quarter. The Chemicals and Plastics Sectors continued their strong growth. The **operating margin** (REBIT on sales) improved to 12.8% compared to 12.6% in the 1<sup>st</sup> half of 2006.

The **net income of the Group** amounted to EUR 413 million (-15%) compared to EUR 484 million in the 1<sup>st</sup> half of 2006. It reached EUR 195 million (-21%) in the 2<sup>nd</sup> quarter of 2007. In the 1<sup>st</sup> half of 2007 it included non-operating items with a negative balance of EUR 34 million, whereas in the 1<sup>st</sup> half of 2006 it included a positive balance of EUR 17 million. Also, tax charges (EUR 146 million) were higher than in the 1<sup>st</sup> half of 2006 (EUR 97 million), which had the benefit of tax credits.

**Cash flow**<sup>3</sup> for the 1<sup>st</sup> half of 2007 amounted to EUR 664 million and **REBITDA**<sup>4</sup> to EUR 850 million. The **net debt to equity ratio** reached 35% at the end of the 1<sup>st</sup> half of 2007, compared to 38% at the end of the 1<sup>st</sup> half of 2006.

The operating results of the **Pharmaceuticals sector** (EUR 205 million) were down by 16% in the 1<sup>st</sup> half of 2007. After a stable 1<sup>st</sup> quarter, results for the 2<sup>nd</sup> quarter 2007 were down by 32% compared to the 2<sup>nd</sup> quarter of 2006; the latter included the gain on sales of non strategic drugs and a compensation, for a total amount of EUR 21 million. Results continued to be affected by the unfavorable impact of the USD (effect of -3% on sales), expiration of marketing rights to Pantoloc® (effect of -6%) and significant pressure on prices in the European pharmaceuticals market, especially in France (effect of -2%). These were partially offset by an increase in sales of other products and the "Inspire" savings plan (EUR 300 million by 2010) which is continuing as planned. Expenses in Research & Development, high in the 2<sup>nd</sup> quarter (17.9%), reached 16% of sales in the 1<sup>st</sup> half of 2007, in line with the estimate for the year.

For 2007, prospects for the Pharmaceuticals Sector remain in line with those presented in the 1<sup>st</sup> quarter of 2007 (see page 9).

The **Chemicals Sector** continued its growth due to the persistence of a continued favorable global balance between supply and demand. Sales (EUR 1,528 million) were comparable (+1%) to those of the 1<sup>st</sup> half of 2006 (+2% in the 2<sup>nd</sup> quarter). Results (REBIT of EUR 189 million) recorded a growth of 10% in the 1<sup>st</sup> half (+14% in the 2<sup>nd</sup> quarter). The "Minerals" and "Oxygen" clusters as well as the "Electrochemistry" (caustic soda) activities continued to record excellent results, while the fluor chemical commodities remained under heavy pressure

The **Plastics Sector** again showed improvement due to the excellent performance of all of its activities. Specialty Polymers made steady progress and the "Vinyls" cluster showed strong growth. Sales (EUR 2,029 million) increased by 6% (+5% in the 2<sup>nd</sup> quarter). Results (REBIT of EUR 245 million) increased by 13% (+11% in the 2<sup>nd</sup> quarter) despite the unfavorable effect of the USD and JPY exchange rate.

**"Overall for 2007, we confirm our confidence that we can achieve the excellent operating results of last year. Obviously, we remain attentive to the evolution of global macroeconomic conditions, energy costs and the EUR/USD exchange rate."**

1 Non-recurring items and results from discontinued operations

2 Operating results, i.e. EBIT before non-recurring items

3 Net income plus total depreciation.

4 REBITDA : REBIT, before recurring depreciation and amortization.

## SOLVAY Group – Summary Financial Information<sup>5</sup>

<i>Million EUR (except for per-share figures in EUR)</i>	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007	1 <sup>st</sup> half 2007/ 1 <sup>st</sup> half 2006	2 <sup>nd</sup> quarter 2006	2 <sup>nd</sup> quarter 2007	2 <sup>nd</sup> quarter 2007/ 2 <sup>nd</sup> quarter 2006
<b>Sales</b>	<b>4,744</b>	<b>4,808</b>	<b>+1%</b>	<b>2,388</b>	<b>2,436</b>	<b>+2%</b>
<b>REBIT</b>	<b>597</b>	<b>616</b>	<b>+3%</b>	<b>304</b>	<b>291</b>	<b>-4%</b>
<i>REBIT/Sales</i>	12.6%	12.8%		12.7%	11.9%	
Non-recurring items	-86	-34	-61%	2	-25	ns
<b>EBIT</b>	<b>511</b>	<b>582</b>	<b>+14%</b>	<b>306</b>	<b>265</b>	<b>-13%</b>
Charges on net indebtedness	-44	-38	-14%	-23	-19	-15%
Income from investments	12	14	+22%	12	14	+22%
<b>Earnings before taxes</b>	<b>478</b>	<b>559</b>	<b>+17%</b>	<b>295</b>	<b>261</b>	<b>-12%</b>
Income taxes	-97	-146	+51%	-49	-66	+35%
Discontinued operations	103	0	ns	0	0	ns
<b>Net income of the Group</b>	<b>484</b>	<b>413</b>	<b>-15%</b>	<b>246</b>	<b>195</b>	<b>-21%</b>
Net income (Solvay share)	468	392	-16%	236	183	-23%
Total depreciation	265	251	-5%	146	128	-13%
REBITDA	826	850	+3%	420	410	-2%
Cash flow	749	664	-11%	392	322	-18%
<i>(per share, in EUR)</i> <b>Earnings per share<sup>6</sup></b>	<b>5.66</b>	4.74	-16%	<b>2.86</b>	2.22	-23%
Net debt to equity	38%	35%				

### Notes on Solvay Group summary financial information

**Non-recurring items** amounted to EUR -34 million in the 1<sup>st</sup> half of 2007 compared to EUR -86 million in the 1<sup>st</sup> half of 2006. They represent, on balance, mainly in the Pharmaceuticals Sector, restructuring costs (EUR 25 million) of the “INSPIRE<sup>7</sup>” project by 2010 and a reversal of provisions no longer needed (EUR 10 million).

**Charges on net indebtedness** amounted to EUR 38 million. At the end of June 2007, about 84% of the financial debt was covered at a fixed rate of 5.5% with a duration of more than 8 years.

**Income taxes** amounted to EUR 146 million in the 1<sup>st</sup> half of 2007, or a rate of 26% (compared to 20% in the 1<sup>st</sup> half of 2006, which had the benefit of tax credits in Germany and Spain and a non-taxable capital gain on the sale of 49.6% of S.A. Financière Keyenveld in the 2<sup>nd</sup> quarter).

In the 1<sup>st</sup> half of 2007, there were no results from **discontinued operations**, whereas that item amounted to EUR 103 million net of taxes in 2006 following the sale in March of industrial foils to Renolit.

**Net income of the Group** amounted to EUR 413 million compared to EUR 484 million in the 1<sup>st</sup> half of 2006. **Net earnings per share** in the 1<sup>st</sup> half of 2007 amounted to 4.74 EUR (2.22 EUR in the 2<sup>nd</sup> quarter of 2007) compared to 5.66 EUR for the same period in 2006 (2.86 EUR in the 2<sup>nd</sup> quarter of 2006).

<sup>5</sup> Financial statements with limited review by Deloitte

<sup>6</sup> Calculated on the basis of the weighted average of the number of shares outstanding after deducting shares purchased to cover stock options, or a total of 82,664,534 shares in the 1<sup>st</sup> half of 2006 and 82,723,341 shares in the 1<sup>st</sup> half of 2007.

<sup>7</sup> See also comments page 8.

**Cash flow** amounted to EUR 664 million, and **REBITDA** to EUR 850 million. **Depreciation** was down by EUR 14 million compared to the 1<sup>st</sup> half of 2006, which included non-recurring depreciation linked to the reorganization of barium and strontium activities.

**Total equity** amounted to EUR 4,711 million at the end of June 2007, up by EUR 255 million compared to the end of 2006. **Net debt** of the Group at the end of June 2007 (EUR 1,662 million) was up by EUR 405 million compared to that of December 31, 2006 and is comparable to that of the 1<sup>st</sup> half of 2006. The **net debt to equity** ratio was 35% at the end of the 1<sup>st</sup> half of 2007, compared to 38% at the end of the 1<sup>st</sup> half of 2006 and 28% at the end of 2006. This situation reflects the Group's policy of having a sound financial situation, in line with the objective of not persistently exceeding a net debt to equity ratio of 45%.

## **RESULTS BY SECTOR<sup>8</sup>**

<i>Million EUR</i>	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007	1 <sup>st</sup> half 2007/ 1 <sup>st</sup> half 2006	2 <sup>nd</sup> quarter 2006	2 <sup>nd</sup> quarter 2007	2 <sup>nd</sup> quarter 2007/ 2 <sup>nd</sup> quarter 2006
<b>GROUP SALES</b>	<b>4,744</b>	<b>4,808</b>	<b>+1%</b>	<b>2,388</b>	<b>2,436</b>	<b>+2%</b>
Pharmaceuticals	1,320	1,251	-5%	648	627	-3%
Chemicals	1,509	1,528	+1%	757	773	+2%
Plastics	1,916	2,029	+6%	983	1,037	+5%
"Corporate et Support activities" <sup>9</sup>	-	-	-	-	-	-
<b>GROUP REBIT</b>	<b>597</b>	<b>616</b>	<b>+3%</b>	<b>304</b>	<b>291</b>	<b>-4%</b>
Pharmaceuticals	243	205	-16%	120	81	-32%
Chemicals	172	189	+10%	84	96	+14%
Plastics	217	245	+13%	113	126	+11%
"Corporate and Support activities" <sup>9</sup>	-35	-23	-34%	-13	-11	-13%
<b>GROUP REBITDA</b>	<b>826</b>	<b>850</b>	<b>+3%</b>	<b>420</b>	<b>410</b>	<b>-2%</b>
Pharmaceuticals	294	256	-13%	146	106	-27%
Chemicals	254	269	+6%	125	137	+9%
Plastics	308	342	+11%	159	175	+10%
"Corporate and Support activities" <sup>9</sup>	-29	-17	-42%	-10	-8	-19%

<sup>8</sup> Results by sector include results from the three sectors of the Group as well as the "Corporate and Business Support"

<sup>9</sup> Non-allocated items, after more direct allocations starting 2007.

# IFRS FINANCIAL STATEMENTS

## CONSOLIDATED INCOME STATEMENT

<i>Million EUR</i> <i>(except for per-share figures, in EUR)</i>	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007	2 <sup>nd</sup> quarter 2006	2 <sup>nd</sup> quarter 2007
<b>Sales</b>	<b>4,744</b>	<b>4,808</b>	<b>2,388</b>	<b>2,436</b>
Cost of goods sold	-3,073	-3,147	-1,551	-1,605
<b>Gross margin</b>	<b>1,671</b>	<b>1,661</b>	<b>837</b>	<b>831</b>
Commercial and administrative costs	-776	-747	-386	-381
Research and development costs	-288	-274	-145	-149
Other operating gains and losses	3	-8	5	-4
Other financial gains and losses	-13	-15	-7	-7
<b>REBIT</b>	<b>597</b>	<b>616</b>	<b>304</b>	<b>291</b>
Non-recurring items	-86	-34	2	-25
<b>EBIT</b>	<b>511</b>	<b>582</b>	<b>306</b>	<b>265</b>
Charge on net indebtedness	-45	-38	-23	-19
Income from investments	12	14	12	14
<b>Earnings before taxes</b>	<b>478</b>	<b>559</b>	<b>295</b>	<b>261</b>
Income taxes	-97	-146	-49	-66
Discontinuing operations	103	0	0	0
<b>Net income of the Group</b>	<b>484</b>	<b>413</b>	<b>246</b>	<b>195</b>
Minority interests	-16	-21	-10	-11
<b>Net income (Solvay share)</b>	<b>468</b>	<b>392</b>	<b>236</b>	<b>183</b>
Earnings per share (in EUR)	5.66	4.74	2.86	2.22
Diluted income per share <sup>(*)</sup> (in EUR)	5.64	4.71	2.85	2.20

(\*) calculated on the number of shares diluted by awarded stock options

## CONSOLIDATED CASH FLOW STATEMENT

<i>Million EUR</i>	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007
EBIT	511	582
Depreciation, amortization and impairments	265	251
Changes in working capital	-318	-485
Changes in provisions	50	-77
Income taxes paid	-120	-94
Others	-118	1
<b>Cash flow from operating activities</b>	<b>270</b>	<b>178</b>
Acquisition/sale of investments	294	-38
Acquisition/sale of assets	-219	-246
Income from investments	12	14
Changes on financial receivables	36	-25
Effect of changes in method of consolidation	2	3
<b>Cash from investing activities</b>	<b>125</b>	<b>-292</b>
Variation of capital (increase/decrease)	-5	-5
Acquisition/sale of own shares	-24	-29
Changes in borrowings	479	451
Charges on net indebtedness	-45	-38
Dividends paid	-230	-232
<b>Cash flow from financing activities</b>	<b>175</b>	<b>146</b>
<b>Net change in cash and cash equivalents</b>	<b>571</b>	<b>32</b>
Currency translation differences	-17	3
Opening cash balance	457	433
<b>Closing cash balance</b>	<b>1,011</b>	<b>469</b>

## CONSOLIDATED BALANCE SHEET

<i>Million EUR</i>	As of December 31, 2006	As of June 30, 2007
<b>Non-current assets</b>	<b>7,276</b>	<b>7,442</b>
Intangible assets	721	703
Goodwill	1,214	1,216
Tangible assets	3,869	3,903
Other investments	790	785
Deferred tax assets	506	624
Financial receivables and other non-current assets	176	211
<b>Current assets</b>	<b>3,825</b>	<b>4,102</b>
Inventories	1,221	1,288
Trade receivables	1,671	1,909
Income tax receivables	95	57
Other receivables	405	378
Cash and cash equivalents	433	469
Assets held for sale	-	0
<b>TOTAL ASSETS</b>	<b>11,101</b>	<b>11,545</b>
<b>Total share capital</b>	<b>4,456</b>	<b>4,711</b>
Share capital	1,271	1,271
Provisions	2,943	3,180
Minority interests	242	260
<b>Non-current liabilities</b>	<b>3,966</b>	<b>4,141</b>
Long-term provisions	2,271	2,238
Deferred tax liabilities	137	258
Long-term financial debt	1,503	1,575
Other non-current liabilities	55	71
<b>Current liabilities</b>	<b>2,679</b>	<b>2,694</b>
Short-term provisions	215	167
Short-term financial debt	188	555
Trade liabilities	1,269	1,221
Income tax payable	99	110
Other current liabilities	908	641
Liabilities associated with assets held for sale	-	0
<b>TOTAL LIABILITIES</b>	<b>11,101</b>	<b>11,545</b>

## STATEMENT OF CHANGES IN EQUITY

<i>Million EURO</i>	Equity attributable to equity holders of the parent						Total	Minority interests	Total equity
	Share capital	Issue premiums	Retained earnings	Treasury shares	Currency translation differences	Fair value differences			
<b>Book value at the end of the period (12/31/2006)</b>	<b>1,271</b>	<b>18</b>	<b>3,284</b>	<b>-138</b>	<b>-420</b>	<b>200</b>	<b>4,214</b>	<b>242</b>	<b>4,456</b>
Net profit for the period			392				392	21	413
Income and expenses directly allocated to equity					10	4	14	10	24
Cost of stock options			3				3		3
Dividends			-143				-143	-4	-147
Acquisition/sale of own shares				-29			-29		-29
Increase in capital									
Other variations								-9	-9
<b>Book value at the end of the period (6/30/2007)</b>	<b>1,271</b>	<b>18</b>	<b>3,536</b>	<b>-167</b>	<b>-411</b>	<b>204</b>	<b>4,451</b>	<b>260</b>	<b>4,711</b>

## **RESULTS BY SECTOR<sup>8</sup>**

The following table provides sales without elimination of sales between sectors as well as results by sector including non-recurring items (EBIT).

<i>Million EUR</i>	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007	1 <sup>st</sup> half 2007/ 1 <sup>st</sup> half 2006	2 <sup>nd</sup> quarter 2006	2 <sup>nd</sup> quarter 2007	2 <sup>nd</sup> quarter 2007/ 2 <sup>nd</sup> quarter 2006
<b>GROUP SALES</b>	<b>5,038</b>	<b>5,111</b>	<b>+1%</b>	<b>2,538</b>	<b>2,593</b>	<b>+2%</b>
Pharmaceuticals	1,320	1,251	-5%	648	627	-3%
Chemicals	1,638	1,660	+1%	825	842	+2%
Plastics	2,080	2,200	+6%	1,065	1,125	+6%
“Corporate and Support Activities <sup>9</sup> “	-	-	-	-	-	-
<b>GROUP EBIT</b>	<b>511</b>	<b>582</b>	<b>14%</b>	<b>306</b>	<b>265</b>	<b>-13%</b>
Pharmaceuticals	139	185	33%	97	64	-34%
Chemicals	-94 <sup>10</sup>	180	ns	-144 <sup>10</sup>	89	ns
Plastics	217	241	11%	113	124	10%
“Corporate et Support activities <sup>9</sup> “	249 <sup>10</sup>	-23	ns	240 <sup>10</sup>	-12	ns

<sup>10</sup> Mainly following the transfer of non-recurring provisions to cover the fines in Europe and the United States in the area of peroxides from “non-allocated items” to “Chemicals Sector”.

## ANNEX TO PRESS RELEASE COMMENTS ON SOLVAY GROUP RESULTS FOR THE 1<sup>ST</sup> HALF OF 2007

### PHARMACEUTICALS SECTOR

#### Strategic developments

- ♦ **Continued strategic transformation of the Pharmaceuticals Sector**  
**United States : Application for registration of bifeprunox (for schizophrenia) being reviewed by the FDA and preparation of the registration application for SLV348 (new product in the fenofibrate franchise)**

Since the acquisition of Fournier in 2005, Solvay Pharmaceuticals has implemented a strategy for transforming its organization (the INSPIRE project). The Sector is aiming for average growth in sales<sup>11</sup> higher than the industry average (estimated in 2005 at 7% per year<sup>12</sup>), and an operating margin of 20% by 2010. To do this, it is prioritizing allocation of R&D resources on two primary therapeutic areas (cardio-metabolic and neuroscience), as well as the well-targeted niches of flu vaccines and pancreatic enzymes. In gastroenterology and men's and women's health, its emphasis is on promoting well-established existing products. In addition, Solvay Pharmaceuticals set a goal of EUR 300 million in annual cost savings by 2010. The implementation of this savings plan is continuing as planned. After integration of the national sales teams as well as the administrative and support functions in 2006, globalization of R&D functions and production is underway, in line with the selection of the priority therapeutic areas. This includes among others the sale of two sites in Baudette (United States) and the ongoing sale of the Veenendaal (Netherlands) site and the vitamin D activities.

Important steps were taken in developing molecules in the portfolio :

- ♦ The review procedure by the FDA (Food and Drug Administration) of the United States application for marketing approval for bifeprunox has been in progress since December 2006. Recently, more detailed clinical results were presented during ICSR<sup>13</sup>. These confirmed bifeprunox's favorable profile with regard to undesirable side effects generally observed in schizophrenia treatments.
- ♦ In the area of fenofibrates, Solvay Pharmaceuticals is pursuing development of new products alongside TriCor®/Lipanthyl®, especially the molecule ABT335/SLV348<sup>14</sup>, a next-generation fenofibrate co-developed with Abbott and now in Phase III. Submission of the application in the United States is scheduled for the 2<sup>nd</sup> half of 2007. Solvay is also developing several combinations of fenofibrate with other molecules. Also, AstraZeneca and Abbott announced the joint development and marketing in the United States of a fixed-dose product, combining Crestor® (the rosuvastatin from AstraZeneca) and either TriCor® 145 NFE or ABT335/SLV348; the filing for this combination product is expected to occur in 2009.
- ♦ At the end of 2007, the new production unit for cell-based flu vaccines will start to produce vaccines for various government contracts for pre-pandemic vaccines as well as vaccines for clinical trials for the flu season, with marketing planned in 2008. Expansion of US clinical trials is in preparation in the framework of the awarded grant<sup>15</sup> of USD 298 million from the health and social services agency<sup>16</sup>.

In addition, the Pharmaceuticals Sector accelerated its geographical deployment by reinforcing its commercial activities in emerging regions (Russia, India, China and Latin America).

11 Based on proforma sales from 2004 including Fournier Pharma, or EUR 2,338 million

12 Industry growth estimates in 2007 at 5% (source : IMS in constant dollars)

13 ICSR : "International Congress on Schizophrenia Research" held from March 28 to April 1, 2007 in the United States (Colorado).

14 Previously called HEXA

15 Subsidy for development of a cell-based flu vaccine and design of a production unit in the United States for 2011.

16 Health and Human Services or HHS

## Key figures

### Key figures for principal products by therapeutic class

Million EUR	2006	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007	1 <sup>st</sup> half 2007 / 1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007 / 1 <sup>st</sup> half 2006 (at constant exchange rate)
<b>PHARMACEUTICALS SECTOR</b>	<b>2,601</b>	<b>1,320</b>	<b>1,251</b>	<b>-5%</b>	<b>-3%</b>
<b>CARDIO-METABOLICS</b>	<b>686</b>	<b>371</b>	<b>362</b>	<b>-2%</b>	<b>+1%</b>
Fenofibrate	413	229	209	-9%	-4%
Teveten®	95	47	52	+11%	+11%
Physiotens®	50	27	26	-4%	-4%
<b>NEUROSCIENCE</b>	<b>430</b>	<b>224</b>	<b>229</b>	<b>+2%</b>	<b>+6%</b>
Serc®	146	78	79	+1%	+2%
Marinol®	106	50	57	+14%	+22%
Luvox®	81	46	44	-4%	+2%
<b>FLU VACCINES</b>	<b>148</b>	<b>24</b>	<b>22</b>	<b>-8%</b>	<b>-8%</b>
Influvac®	118	12	7	-42%	-43%
<b>PANCREATIC ENZYMES (Creon®)</b>	<b>191</b>	<b>96</b>	<b>96</b>	<b>0%</b>	<b>+2%</b>
<b>GASTROENTEROLOGY</b>	<b>294</b>	<b>188</b>	<b>116</b>	<b>-38%</b>	<b>-37%</b>
Duphalac®	85	45	49	+9%	+8%
Duspatal®	59	31	31	0%	-1%
Pantoloc®	70	72	-	-	-
<b>MEN'S AND WOMEN'S HEALTH</b>	<b>599</b>	<b>309</b>	<b>319</b>	<b>+3%</b>	<b>+9%</b>
AndroGel®	275	141	160	+13%	+23%
Duphaston®	74	39	42	+8%	+6%
Prometrium®	76	40	40	0%	+9%

## Comments

- Pharmaceuticals Sector Sales In the **1<sup>st</sup> half of 2007**, were EUR 1,251 million (-5%).

There was a decrease of 6% due to the expiration of marketing rights to Pantoloc® in May 2006 (EUR 72 million in 5 months 2006) as well as the negative effect (-3%, or EUR 40 million) of the USD/EUR exchange rate on sales in the US. Those sales improved by +6% in USD (to USD 606 million), reflecting the favorable evolution in prescriptions for the main products, while it dropped by 2% in EUR. In Europe, pressure on prices remained strong, especially in France (negative impact of EUR 30 million). The growth of sales in some of the emerging and developing countries (such as Mexico and Turkey) however mitigated the effects.

Sales in the cardio-metabolic area included EUR 209 million of income from fenofibrates (TriCor® and Lipanthyl®). Sales of TriCor® 145mg NFE (USD 526 million) booked by Abbott in the United States improved by 15% in USD. Under the cumulative unfavorable effect of the USD and temporary lower product orders by Abbott during the 1st half, this performance by TriCor® did not have yet the same impact on Solvay revenue. Outside the United States, sales of fenofibrates were significantly up in countries where it was recently launched (Australia, Turkey, etc.) while they were down in countries such as France and Canada. In neuroscience, Marinol® improved by 14% in EUR; in its primary market, the United States, it improved by 23% in USD (+14% in EUR). Sales of AndroGel® in the American market rose sharply (+23% in USD and +13% in EUR).

- The Pharmaceuticals Sector is actively pursuing its **research** efforts in the Neuroscience and Cardiometabolic areas, in particular the more rapid development of successors to Tricor®/Lipanthyl® to reinforce the fenofibrate franchise value. Duodopa and SLV308 (in Phase III) were a significant part of R&D efforts. R&D efforts rose to EUR 203 million compared to EUR 217 million in the 1<sup>st</sup> half of 2006, in line with the estimate of 16% of sales for 2007.
- **Operating results** of the Pharmaceuticals Sector amounted to EUR 205 million and dropped by 16%. After a stable 1<sup>st</sup> quarter, results for the 2<sup>nd</sup> quarter 2007 (EUR 81 million), as a consequence of the items mentioned above, decreased by 32% compared to the 2<sup>nd</sup> quarter of 2006. The latter included the gain on sales of non strategic drugs and a compensation, for a total amount of EUR 21 million. In addition, research efforts were particularly supported which brought the ratio of R&D to sales to 17.9% for this quarter (compared to 16% expected for 2007).

The **operating margin** of the Pharmaceuticals Sector in the 1<sup>st</sup> half of 2007 was 16.4% compared to 18.4% in the 1<sup>st</sup> half of 2006 and 17.3% for 2006.

- The implementation of the **plan to save EUR 300 million by 2010** is continuing on course; restructuring costs of EUR 25 million were recorded during the 1<sup>st</sup> half of 2007.

*For the year 2007, the outlook for the Pharmaceuticals Sector remain consistent with the one presented in the 1<sup>st</sup> quarter of 2007.*

*“Solvay Pharmaceuticals is anticipating stabilization of sales, in view of the impact of the USD to EUR exchange rate on American sales and the loss of marketing rights for Pantoloc®.*

*Savings realized through the Inspire project will permit sector results to be sustained, while maintaining research efforts and preparing the commercial launch of bifeprunox. This forecast also includes the favorable impact of the flu vaccine, Influvac®, in the 2<sup>nd</sup> half. “*

## CHEMICALS SECTOR

### Strategic developments

- ♦ ***Sustain growth and competitiveness by intensification of geographic expansion, continued technological innovation, development of specialties and targeted restructuring.***

Technological innovation and geographic expansion were embodied in two significant developments:

- In hydrogen peroxide, the current construction at Antwerp, in partnership with BASF and Dow, of a mega-plant (230 kt/year) based on the new “high productivity” technology developed by Solvay, to provide hydrogen peroxide for a propylene oxide production unit.
- In epichlorhydrin, startup in France of the 1<sup>st</sup> industrial-scale production unit (10,000 tons/year) using the new Solvay method, Epicerol™, utilizing glycerin derived from the biodiesel industry. Also, a 2<sup>nd</sup> plant is planned by the end of 2009 with a capacity of 100 kt/year in Thailand, in order to meet the rapidly growing demand in Asia.

This also includes the joint venture agreement with Lantian in China for production of hydrogen fluoride and the startup in mid-2007 at Onsan (Korea) of a new fluorinated specialties plant. The new plant is designed to serve high-growth markets in this region of the world such as semi-conductors and liquid-crystal screens (LCDs).

In Bulgaria, Solvay Sodi announced expansion for 2008 of its annual production capacity of soda ash to 1.5 million tons (from to 1.2 million tons) in addition to significant investments aiming to modernize energy supply at the site.

Additionally, in light of the intense competitive pressures in fluorinated commodities, a global study of improvement of profitability and prospects for all of the fluorinated chemical activities is under way. It led, at this stage, to a reorganization program of the sites in Germany. Additional measures in our industrial activities in refrigerants are under study.

The combination of the Barium Strontium and Advanced Functional Minerals activities into one single Strategic Business Unit called Advanced Functional Minerals was effective on January 1, 2007; it is intended to reinforce synergies, primarily in research and development of new high-added-value specialties.

Finally, the Chemicals Sector is paying particular attention to developments in the energy situation and is multiplying initiatives to mitigate the effect (through technological leadership, high-performance industrial infrastructures, cogeneration units, and a strategy of supply coverage with medium- to long-term contracts). Solvay's participation in the Exeltium consortium, a group of electric-intensive industries in France, should provide large production sites in France with long-term energy supplies at competitive prices. In Belgium a feasibility study for a similar project is currently under way. Also, as permitted by the specific market conditions for each SBU, price hikes were negotiated to compensate for high energy costs.

## Key figures

(million EUR)	Sales				REBIT change
	2006	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007	1 <sup>st</sup> half 07/1 <sup>st</sup> half 06 %	1 <sup>st</sup> half 07 / 1 <sup>st</sup> half 06
<b>CHEMICALS</b>	<b>2,998<sup>18</sup></b>	<b>1,509<sup>18</sup></b>	<b>1,528<sup>18</sup></b>	<b>+1%</b>	<b>+10%</b>
“Minerals” <sup>19</sup> cluster	1,304	649	659	+2%	↗
“Electrochemistry and fluor chemicals cluster”	1,130	584	572	-2%	↗
“Oxygen cluster” <sup>20</sup>	495	242	261	+8%	↗

## Comments

- ◆ **Continued growth in Chemicals activities thanks to overall favorable market conditions, despite continued high energy costs.**

The **Chemicals Sector** continued its growth due to the persistence of a continued favorable global balance between supply and demand. Sales (EUR 1,528 million) were comparable (+1%) to those of the 1<sup>st</sup> half of 2006 (+2% in the 2<sup>nd</sup> quarter). Results (REBIT of EUR 189 million) recorded a growth of 10% in the 1<sup>st</sup> half (+14% in the 2<sup>nd</sup> quarter). The “Minerals” and “Oxygen” clusters as well as the “Electrochemistry” (caustic soda) activities continued to record excellent results, while the fluor chemical commodities remained under heavy pressure

- **Soda ash** activities improved due to continuing increased demand and rising prices in the context of very high energy costs. The growth of specialty derivatives of soda ash, bicarbonate in particular, continued due to the development of a portfolio of products and geographic expansion.
- Results from **Electrochemistry** increased in the 1<sup>st</sup> half of 2007. Volumes of caustic soda remained good, in particular in the paper, aluminum and chemistry sectors. Customer inventory levels remained low in the 1<sup>st</sup> half of 2007 while supply remained strained due to continued technical problems at several European producers in the 2<sup>nd</sup> quarter of 2007, keeping the prices high.
- **Fluoride products** results continued to be impacted on the one hand by an increase in energy costs in Europe and on the other hand by a significant erosion of prices in the refrigerants market, linked to intensification of competitive pressure from China for Solkane® 134a.
- Results from **Hydrogen Peroxide** improved due to growth in volumes in all the regions and energy costs under control. Also, in comparison with last year, the SBU is now fully benefiting from expansion of capacities started at the beginning of April 2006.

## PLASTICS SECTOR

### Strategic developments

- ◆ **Capitalizing on our strengths, enriching the portfolio of activities : acceleration of geographic development in Russia, Asia and South America.**

The strategy of the Plastics Sector is characterized:

- On the one hand, by the development of Specialties: Specialty Polymers and Inergy Automotive Systems, a 50/50 joint venture with Plastic Omnium in fuel systems. These high-value-added activities are now among the primary contributors to the Group’s results.

The Group is considerably reinforcing its competitive position in Specialty Polymers in order to meet the growing demand from markets such as electronics, aerospace, medical applications, automotive, etc. It is emphasizing internal growth projects, expansion of the portfolio of products, including through acquisitions, as well as geographic expansion, in particular in Asia. Internal growth projects are focused around tripling polysulfone production capacity and expansion of capacities for numerous other polymers. Acquisitions in 2006 (Mississippi Polymer Technologies (United States) and Gharda (India)) completed the portfolio of activities. They provided access to very-high-performance polymers, including PEEK, for which a commercial-scale production unit is being constructed in Panoli (India). In Asia, a Technical Center was opened in China

<sup>18</sup> Including SBU Molecular Solutions

<sup>19</sup> Including Soda Ash and Derivatives SBUs as well as Advanced Functional Minerals (combining Barium Strontium derivatives and Advanced Functional Minerals since 01/01/2007).

<sup>20</sup> Including Hydrogen Peroxide, Detergents and Caprolactones SBUs

and a world-class plant is being built to produce micronized PTFE, used in cosmetics or for high-performance lubricants. Finally of note is the 50/50 joint venture between Solvay and Umicore, SolviCore, for research, development, production and marketing of membrane-electrode assemblies (AME), designed for application in fuel cells (PC).

- On the other hand, in the Vinyls activities, by strong leadership on three continents (Europe, Mercosur and Asia), targeted growth and continuous reinforcement of competitiveness which remain the priorities for the Vinyls cluster.

SolVin (a joint venture held 75% by Solvay and 25% by BASF) took a significant step in its geographic development by recently concluding a 50/50 joint venture with Sibur, a subsidiary of Gazprom, for the construction in Russia, by 2010, of the 1<sup>st</sup> entirely integrated plant, with a nominal capacity of 330 kt of PVC in the framework of a world-class unit of 510 kt. Also, SolVin's competitive position in Europe was further reinforced with shutdown of the unit at Ludwigshafen on January 1, 2006 and the transfer of production to other units. In this context and given the growth in demand in Europe, it was decided to increase capacity at the site of Jemeppe (Belgium) from 400 kt/year to 475 kt/year by 2009. The Thai affiliate, Vinythai, doubled its capacities in 2006 (salt/chorine/EDC/VCM) and an expansion of 70 kt/year of PVC is under way in Thailand with startup projected for mid-2008. In South America, capacity expansion in chlorine, caustic soda, VCM and PVC are also continuing in Brazil, with a startup planned for mid-2008. Southeast Asia, Mercosur and henceforth Russia constitute, along with Europe, significant areas of growth for the Vinyls activities.

## Key figures

(million EUR)	Sales				REBIT Change
	2006	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007	1 <sup>st</sup> half 07/1 <sup>st</sup> half 06 %	1 <sup>st</sup> half 07/1 <sup>st</sup> half 06
<b>PLASTICS</b>	<b>3.800</b>	<b>1.916</b>	<b>2,029</b>	<b>+6%</b>	<b>+13%</b>
Specialties <sup>21</sup>	1,712	895	894	-	↗
Vinyls cluster <sup>22</sup>	2,088	1,020	1,134	+11%	↗

## Comments

- ◆ **Growth in “Specialties” cluster and continued strong growth in “Vinyls” cluster**

The **Plastics** Sector again showed improvement due to the excellent performance of all of its activities. Specialty Polymers made steady progress and the “Vinyls” cluster showed strong growth. Sales (EUR 2,029 million) increased by 6% (+5% in the 2<sup>nd</sup> quarter). Results (REBIT of EUR 245 million) increased by 13% (+11% in the 2<sup>nd</sup> quarter) despite the unfavorable effect of the USD and JPY exchange rate.

- **Specialty Polymers** recorded growth in volume in the 1<sup>st</sup> half of 2007. Demand was particularly strong in the high-added-value markets such as consumer electronics, aerospace, medical applications, pharmaceutical packaging and petroleum-drilling applications. Sales also improved significantly in Asia, where activities were reinforced (12% of sales for 2006). Results continued to improve compared to the very good level reached in the 1<sup>st</sup> half of 2006 despite the effect of the unfavorable exchange rate between the Yen and the USD and the sustained R&D efforts (5% of sales) in order to meet the demand for new high-performance polymers.

Results from **Inergy Automotive Systems** in the 1<sup>st</sup> half of 2007 were comparable to those of the 1<sup>st</sup> half of 2006 due to efforts to improve competitiveness and industrial redeployment such as shutdown of a plant in Japan planned for this year. Total volumes (6.7 million fuel systems) decreased (-4%) compared to the 1<sup>st</sup> half of 2006, due to a marked slowdown of its customers in NAFTA, Western Europe and Japan. Production in Eastern Europe is showing strong improvement. Developments in high-growth areas (such as Russia, India, China, etc.) are under way and new platforms using innovative technologies were acquired.

- Results from **Vinyls** were up significantly, especially in Europe, due to overall better spreads, growth in worldwide demand and a reinforced competitive position. In Europe, demand remains good and is particularly strong in Eastern Europe. Price hikes occurred starting June while the price of ethylene is rising. Demand in Mercosur continues its strong growth (+13% on average). In Asia, market trends are improving for vinyls, while Chinese competition underwent increases in costs and pressure on its exports. Prospects remain overall favorable.

Results from **Pipelife** (pipes and fittings) were up significantly, due to increases in volumes everywhere in Europe, and in particular in Eastern Europe and Scandinavia. Development of the range of products and geographic expansion also contributed to this performance and will be further reinforced in the future because of the acquisition of Quality Plastics in Ireland in April 2007.

<sup>21</sup> Includes Specialty Polymers SBUs and Inergy Automotive Systems (fuel systems)

<sup>22</sup> Includes Vinyls SBUs and Pipelife (pipes and fittings)

## COMMENTS

### 1. Limited Quarterly Review.

Deloitte have conducted a limited review of the consolidated six-month situation that closed on 30 June 2007. This consisted principally of analysis, comparison and discussions of financial information and therefore was less extensive than an audit that would be undertaken for annual statements. This review did not disclose any elements that would have required significant corrections in the intermediate statements.

### 2. Risk Management

A risk management analysis is in the 2006 annual report published on the Internet ([www.solvay-investors.com](http://www.solvay-investors.com)).

### 3. Primary exchange rates

1 Euro =	Closing			Average		
	2006	6 months 2006	6 months 2007	2006	6 months 2006	6 months 2007
Pound Sterling GBP	0.6715	0.6921	0.6740	0.6817	0.6870	0.6746
American Dollar USD	1.3170	1.2713	1.3505	1.2554	1.2288	1.3289
Argentine peso ARS	4.0474	3.9241	4.1697	3.8594	3.7664	4.1055
Brazilian real BRL	2.8144	2.7568	2.5980	2.7329	2.6935	2.7192
Thai baht THB	46.77	48.58	42.62	47.58	47.60	44.71
Japanese yen JPY	156.93	145.75	166.63	146.03	142.11	159.58

### 4. Solvay Shares

	2006	1 <sup>st</sup> half 2006	1 <sup>st</sup> half 2007
Number of shares issued at the end of the period	84,701,133	84,698,133	84,701,133
Average number of shares for IFRS calculation of earnings per share	82,669,267	82,664,534	82,723,341

\* \* \* \*

#### Key dates for financial communications

- ♦ Wednesday, September 26 2007 : Solvay's Investor Day at Brussels
- ♦ Friday, October 26, 2007 : nine-month results 2007 and announcement of prepayment of dividend for 2007 (payable in January 2008, coupon No. 81) (at 7:30 AM)
- ♦ Friday, February 15, 2008 : annual results for 2007 (at 7:30 AM)

#### To obtain additional information :

##### **Martial TARDY**

Corporate Press Officer

SOLVAY S.A.

Tel: 32 2 509 72 30

E-mail : [martial.tardy@solvay.com](mailto:martial.tardy@solvay.com)

Internet: [www.solvaypress.com](http://www.solvaypress.com)

##### **Patrick VERELST**

Deputy Investor Relations

SOLVAY S.A.

Tel: 32 2 509 72 43

E-mail : [patrick.verelst@solvay.com](mailto:patrick.verelst@solvay.com)

Internet: [www.solvay-investors.com](http://www.solvay-investors.com)

##### **Solvay Investor Relations**

SOLVAY S.A.

Tel. 32-2-509.60.16

E-mail : [investor.relations@solvay.com](mailto:investor.relations@solvay.com)

\* \* \* \*

**SOLVAY** is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs some 29,000 people in 50 countries. In 2006, its consolidated sales amounted to EUR 9.4 billion generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext : SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the NYSE Euronext stock exchange in Brussels.

\* \* \* \*

*Dit persbericht is ook in het Nederlands beschikbaar – Ce communiqué de presse est également disponible en français*